整合多組學(xué)策略為中藥安全性評價開辟了新的研究視角，單細(xì)胞轉(zhuǎn)錄組學(xué)、蛋白質(zhì)修飾組學(xué)、代謝組學(xué)、影像組學(xué)等前沿組學(xué)技術(shù)實(shí)現(xiàn)了從分子、細(xì)胞、組織到系統(tǒng)乃至整體不同層面揭示中藥的毒性效應(yīng)機(jī)制，幫助識別中藥潛在毒性成分并發(fā)現(xiàn)特征生物標(biāo)志物?；谥袊W(wǎng)、PubMed、Web of Science等權(quán)威數(shù)據(jù)庫檢索近10年與多組學(xué)技術(shù)和中藥安全性評價/毒性研究的相關(guān)文獻(xiàn)并進(jìn)行梳理歸納?；仡欀兴幎拘匝芯楷F(xiàn)狀，系統(tǒng)闡述并總結(jié)各類組學(xué)新技術(shù)在中藥毒性研究中的應(yīng)用進(jìn)展，為推動多組學(xué)聯(lián)合應(yīng)用作為中藥毒性研究新策略提供參考。未來高通量數(shù)據(jù)處理技術(shù)的進(jìn)步有望推動多組學(xué)技術(shù)為中藥安全性評價體系的完善作出更大貢獻(xiàn)。

The integration of multi-omics strategies has opened up a new research perspective for the safety evaluation of traditional Chinese medicine. Cutting-edge omics technologies such as single-cell transcriptomics, protein modification omics, metabolomics and imaging omics have realized the mechanism of toxic effects of traditional Chinese medicine (TCM) from different levels of molecules, cells, tissues, systems and even the whole, helping to identify potential toxic components of TCM and discover characteristic biomarkers. Based on CNKI, PubMed, Web of Science and other authoritative databases, literature related to multi-omics technology and TCM safety evaluation/toxicity studies in the past 10 years was searched and summarized. This paper reviewed the status of toxicity research of TCM, systematically expounded and summarized the application progress of various new omics technologies in toxicity research of TCM, and provided reference for promoting the combined application of multi-omics as a new strategy for toxicity research of traditional Chinese medicine. In the future, the progress of high-throughput data processing technology is expected to promote multi-omics technology to make greater contributions to the improvement of traditional Chinese medicine safety evaluation system.

R285

國家自然科學(xué)基金資助項(xiàng)目（82204938）